

This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

In Vitro and in Vivo *Phlebovirus* Inhibition by Nucleosides Related to Ribavirin

John H. Huffman^a; Robert W. Sidwell^a; Roland K. Robins^b; Ganapathi R. Revankar^b; Dominique Y. Pifat^c

^a Dept. of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT ^b ICN Nucleic Acid Research Institute, Costa Mesa, CA ^c U.S. Army Medical Research Institute for Infectious Diseases, Frederick, MD

To cite this Article Huffman, John H. , Sidwell, Robert W. , Robins, Roland K. , Revankar, Ganapathi R. and Pifat, Dominique Y.(1989) 'In Vitro and in Vivo *Phlebovirus* Inhibition by Nucleosides Related to Ribavirin', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 1159 — 1160

To link to this Article: DOI: 10.1080/07328318908054318

URL: <http://dx.doi.org/10.1080/07328318908054318>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

IN VITRO AND IN VIVO PHLEBOVIRUS INHIBITION BY NUCLEOSIDES
RELATED TO RIBAVIRIN

John H. Huffman*, Robert W. Sidwell, Roland K. Robins¹, Ganapathi R.
Revankar¹, and Dominique Y. Pifat²

Dept. of Animal, Dairy and Veterinary Sciences, Utah State University,
Logan, UT 84322-5600, ¹ICN Nucleic Acid Research Institute, Costa Mesa,
CA, and ³U.S. Army Medical Research Institute for Infectious Diseases,
Fort Detrick, Frederick, MD

Abstract: Eleven compounds were compared to ribavirin for their
in vitro and in vivo inhibition of Punta Toro virus (PTV), a phlebovirus
in the Bunyaviridae virus family.

Introduction: These studies were done in an attempt to find
compounds which might be used to overcome diseases due to phlebovirus
infections of humans and animals.

Materials and Methods: Virus: The Adames strain of Punta
Toro virus was prepared in cell culture for all experiments.

Cells: Continuous passaged Rhesus monkey kidney cells (LLC-MK₂
Derivative) were grown in Minimum Essential Medium (MEM) with fetal
bovine serum (FBS) and NaHCO₃, without antibiotics. These cells were
used to prepare virus pools and in all virus titrations. Gentamicin (50
µg/ml) was included in medium in which virus was prepared or titered.

Mice: C57BL/6 mice, 3-4 weeks old, were used for in vivo
antiviral evaluations. They were infected by subcutaneous (s.c.)
injection of the PTV preparations.

Compounds: The compounds used in these experiments were provided
by the U.S. Army Medical Research Institute for Infectious Diseases.

Antiviral evaluations: In vitro experiments were evaluated by use
of inhibition of viral cytopathogenic effect in 96-well microplates as
previously described¹. The 50% effective dose (ED₅₀) was determined for
each compound. The 50% cytotoxic dose (CD₅₀) was also determined by
microscopic examination of concomitantly run toxicity controls for cell
anomalies. The therapeutic index (TI) of each compound was calculated

TABLE 1. COMPARATIVE IN VITRO AND IN VIVO ANTIVIRAL ACTIVITY OF 12 COMPOUNDS VS PUNTA TORO VIRUS

Compound	Number	VR ^a	In vitro TI ^b	In vivo TI ^c
thioformycin B	1	1.5	175	8
ribavirin	2	1.2	90	14
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide hydrochloride	3	1.1	120	32
selenazofurin	4	1.0	16	8
formycin A	5	0.8	8	0
tiazofurin	6	0.8	2	8
ribavirin 2',3',5'-triacetate	7	0.4	4	32
tiazofurin 2',3',5'-triacetate	8	0.4	0.8	≥3
3-deazaguanine	9	0.3	5	8
formycin B	10	0.3	3	8
9-(β-D-ribofuranosyl)purine-6-thiocarboxamide	11	0.2	3	8
3-bromo-4-chloropyrazolo-[3,4-d]-pyrimidine	12	0.05	<1	2

^aVirus Rating.^bMaximum TI obtained (TI = CD50 + ED50) (μg/ml).^cMaximum TI obtained (TI = Maximum Tolerated Dose + Minimum Statistically Effective Dose) (mg/kg/day).

as a measure of antiviral activity (TI = CD50 + ED50). The virus rating (VR) of each compound was also determined¹.

In vivo experiments were evaluated by use of several parameters, but only one (the statistically significant number of survivors 21-days post-virus injection) was utilized in calculations of the TIs shown.

Results and Discussion: The results, sorted by VR, are shown in Table 1. The compounds most active in vivo (2, 3, 6 and 7) were also among the most active compounds seen in vitro with the exception of 7, which had very low in vitro activity. Compound 1 had very low in vivo activity, even though it had the highest in vitro activity. Compounds 2, 3, 6 and 7 were all effective in vivo when given as a single inoculation as late as 48 hr after virus infection.

REFERENCES

1. R.W. Sidwell and J. H. Huffman, *Appl. Microbiol.*, **22**, 797 (1971).

Supported by: DAMD-17-86-C-6028, U.S. Army Medical Research Development Command.